Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,140.40
(
0.52%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.64
(
2.38%
)
Bitcoin
74,785.57
(
-0.08%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech jim post# 177074

Monday, 04/21/2014 4:32:14 PM

Monday, April 21, 2014 4:32:14 PM

Post# of 257253

AGN—Apparently Bill Ackman is teaming up with Valeant to offer a takeout bid. Just reported by a CNBC news flash.

Well, Botox is AGN’s most profitable product by a wide margin, and the competitive landscape for Botox just got more secure.

Still, I question whether VRX can digest so many acquisitions in a short time without botching the effort. Moreover, I don’t think David Pyott is ready to retire, so I wonder what role Ackman and VRX have in mind for him.

All told, this deal is an underdog to be consummated, IMHO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now